Vimarsana
Biggest News Aggregation in the World

Page 5 - Blue Source News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Blue Source. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Blue Source Today - Breaking & Trending Today

Best Stocks For ESG Investors: Our Favorite Is Star Royalties - Vimarsana News

Best Stocks For ESG Investors: Our Favorite Is Star Royalties

ESG has become a prevailing social movement of our time. Read why Star Royalties is the best stock for ESG investors who have a three-year time horizon.

Star Royalties Ltd looking to continue momentum into 2022 as it posts full year financial results - Vimarsana News

Star Royalties Ltd looking to continue momentum into 2022 as it posts full year financial results

Star Royalties Ltd (TSX-V:STRR), the precious metals and carbon credit royalty and streaming company, said it was looking forward to continuing the momentum...

This company is tops in gold royalties, but increasingly green - Vimarsana News

This company is tops in gold royalties, but increasingly green

Strategic partnerships enable Green Star Royalties, Star Royalties' subsidiary, to focus on the growth of its green royalty business model

Green Star Royalties, Bluesour - GuruFocus.com - Vimarsana News

Green Star Royalties, Bluesour - GuruFocus.com

GuruFocus Article or News written by ACCESSWIRE and the topic is about:

NA Proactive news snapshot: AIM ImmunoTech Inc, Cloud DX Inc, XPhyto Therapeutics Corp, Kintara Therapeutics Inc, Empower Clinics Inc, Biocept Inc, Guardforce AI Company Limited, Thor Explorations Ltd, enCore Energy Corp, PyroGenesis Canada Inc, Xigem Tec - Vimarsana News

NA Proactive news snapshot: AIM ImmunoTech Inc, Cloud DX Inc, XPhyto Therapeutics Corp, Kintara Therapeutics Inc, Empower Clinics Inc, Biocept Inc, Guardforce AI Company Limited, Thor Explorations Ltd, enCore Energy Corp, PyroGenesis Canada Inc, Xigem Tec

AIM ImmunoTech Inc presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship...